<p>根据最近向证券交易委员会（SEC）提交的文件，Colonial Trust Advisors 在第四季度将其在史赛克（Stryker Co.，NYSE:SYK - 免费报告）股票中的持仓减少了 2.5%。该基金在出售了 760 股后，持有 29,404 股这家医疗技术公司的股票。截至其最近向证券交易委员会（SEC）提交的文件，Colonial Trust Advisors 在史赛克的持股价值为 10,587,000 美元。</p>
<ul>
<li>如果你只能持有 3 项投资一辈子，请考虑这些</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也对 SYK 的持仓进行了调整。Kohmann Bosshard Financial Services LLC 在第四季度购买了价值约 25,000 美元的史赛克新股份。Rakuten Securities Inc.在第四季度将其在史赛克的持股增加了 618.2%。Rakuten Securities Inc.现在拥有 79 股这家医疗技术公司的股票，价值 28,000 美元，此前在上个季度又收购了 68 股。Centricity Wealth Management LLC 在第四季度购买了价值 30,000 美元的史赛克新股份。BankPlus Trust Department 在第四季度购买了价值 33,000 美元的史赛克新持仓。最后，Activest Wealth Management 在第四季度购买了价值约 36,000 美元的史赛克新持仓。77.09% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>内部买卖</h2>
<p>在其他消息中，董事 Ronda E. Stryker 在 1 月 31 日星期五出售了 201,392 股股票。股票以平均价格 392.24 美元出售，总交易额为 78,993,998.08 美元。出售完成后，该董事现在直接拥有 3,642,075 股公司股票，价值 1,428,567,498 美元。这代表其持股减少了 5.24%。该交易在向 SEC 的文件中披露，相关信息可通过 SEC 网站获取。此外，董事 Allan C. Golston 在 2 月 18 日星期二出售了 2,458 股股票。股票以平均价格 383.07 美元出售，总交易额为 941,586.06 美元。交易完成后，该董事现在直接拥有 14,895 股公司股票，价值约 5,705,827.65 美元。这代表其持股减少了 14.16%。该销售的披露信息可以在这里找到。5.90% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>3 只帮助将人工智能引入医疗保健的股票</li>
</ul>
<p>一些券商最近对 SYK 发布了报告。JMP Securities 在 2 月 18 日的研究报告中重申了对史赛克股票的 “市场表现” 评级。Needham &amp; Company LLC 在 3 月 21 日的研究报告中重新发布了 “买入” 评级，并设定了 442.00 美元的目标价。Canaccord Genuity Group 将史赛克的目标价从 420.00 美元提高到 435.00 美元，并在 1 月 29 日的研究报告中给予该公司 “买入” 评级。Truist Financial 在 1 月 30 日的报告中将史赛克的目标价从 409.00 美元提高到 413.00 美元，并给予该股票 “持有” 评级。最后，Wells Fargo &amp; Company 在 1 月 29 日的报告中将史赛克的目标价从 427.00 美元提高到 435.00 美元，并给予该公司 “增持” 评级。五位分析师对该股票给予了持有评级，十六位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 421.90 美元。</p>
<p><strong>查看我们最新的史赛克股票报告</strong></p>
<h2>史赛克股票上涨 7.7%</h2>
<ul>
<li>史赛克的收购狂潮：双位数增长在望</li>
</ul>
<p>周四，SYK 的开盘价为 363.44 美元。该股票的市值为 1387.2 亿美元，市盈率为 46.84，市盈增长比率为 2.93，贝塔系数为 0.93。史赛克的 12 个月低点为 314.93 美元，12 个月高点为 406.19 美元。该公司的 50 日简单移动平均线为 377.27 美元，200 日简单移动平均线为 373.71 美元。该公司的流动比率为 1.95，速动比率为 1.32，债务与股本比率为 0.59。</p>
<p>史赛克（NYSE:SYK - 获取免费报告）最近在 1 月 28 日星期二宣布了其季度财报。这家医疗技术公司报告第四季度每股收益（EPS）为 4.01 美元，超出分析师共识预期的 3.87 美元，超出幅度为 0.14 美元。史赛克的净利润率为 13.25%，股本回报率为 23.58%。去年同期，该公司每股收益为 3.46 美元。整体来看，研究分析师预计史赛克在当前财年将发布 13.47 美元的每股收益。</p>
<h2>史赛克宣布分红</h2>
<p>该公司最近还披露了季度分红，将于 4 月 30 日星期三支付。3 月 31 日星期一的登记投资者将获得每股 0.84 美元的分红。这相当于年化分红 3.36 美元，收益率为 0.92%。该分红的除息日期为 3 月 31 日星期一。史赛克的分红支付比率为 43.30%。</p>
<h2>史赛克简介</h2>
<p>（免费报告）</p>
<p>史赛克公司作为一家医疗技术公司运营。该公司通过两个部门运营，分别是医疗外科和神经技术，以及骨科和脊柱。骨科和脊柱部门提供用于全关节置换手术的植入物，如髋关节、膝关节和肩关节，以及创伤和四肢手术。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过史赛克</li>
<li>内部买入解释：投资者需要知道的事项</li>
<li>First Solar 股票：是什么推动了四月初的反弹？</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>为什么分析师在财报前提升了联合航空股票</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>Dave &amp; Buster’s 股票：第二季度的短期挤压机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在史赛克吗？</h2>
<p>在考虑史赛克之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄向客户推荐在更广泛的市场注意到之前购买……而史赛克并不在名单上。</p>
<p>尽管史赛克目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

史赛克

<p>殖民信托顾问在第四季度将其在史赛克（NYSE:SYK）的持股减少了 2.5%，目前持有 29,404 股，估值约为 1059 万美元。其他机构投资者也调整了他们的持仓。值得注意的是，董事 Ronda E. Stryker 出售了超过 201,000 股，减少了她的持股比例 5.24%。分析师对史赛克维持 “适度买入” 的共识，目标价为 421.90 美元。该股票开盘价为 363.44 美元，市值为 1387.2 亿美元，最近的每股收益为 4.01 美元，超出预期</p>

<p>Colonial Trust Advisors trimmed its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,404 shares of the medical technology company's stock after selling 760 shares during the quarter. Colonial Trust Advisors' holdings in Stryker were worth $10,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根据最近向证券交易委员会（SEC）提交的文件，Colonial Trust Advisors 在第四季度将其在史赛克（Stryker Co.，NYSE:SYK - 免费报告）股票中的持仓减少了 2.5%。该基金在出售了 760 股后，持有 29,404 股这家医疗技术公司的股票。截至其最近向证券交易委员会（SEC）提交的文件，Colonial Trust Advisors 在史赛克的持股价值为 10,587,000 美元。</p>
</div><ul>
<li>If You Could Only Hold 3 Investments for Life, Consider These</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你只能持有 3 项投资一辈子，请考虑这些</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker in the fourth quarter worth about $25,000. Rakuten Securities Inc. boosted its holdings in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in Stryker in the fourth quarter valued at $30,000. BankPlus Trust Department purchased a new position in Stryker during the fourth quarter valued at $33,000. Finally, Activest Wealth Management purchased a new position in shares of Stryker in the 4th quarter worth about $36,000. 77.09% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也对 SYK 的持仓进行了调整。Kohmann Bosshard Financial Services LLC 在第四季度购买了价值约 25,000 美元的史赛克新股份。Rakuten Securities Inc.在第四季度将其在史赛克的持股增加了 618.2%。Rakuten Securities Inc.现在拥有 79 股这家医疗技术公司的股票，价值 28,000 美元，此前在上个季度又收购了 68 股。Centricity Wealth Management LLC 在第四季度购买了价值 30,000 美元的史赛克新股份。BankPlus Trust Department 在第四季度购买了价值 33,000 美元的史赛克新持仓。最后，Activest Wealth Management 在第四季度购买了价值约 36,000 美元的史赛克新持仓。77.09% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Ronda E. Stryker 在 1 月 31 日星期五出售了 201,392 股股票。股票以平均价格 392.24 美元出售，总交易额为 78,993,998.08 美元。出售完成后，该董事现在直接拥有 3,642,075 股公司股票，价值 1,428,567,498 美元。这代表其持股减少了 5.24%。该交易在向 SEC 的文件中披露，相关信息可通过 SEC 网站获取。此外，董事 Allan C. Golston 在 2 月 18 日星期二出售了 2,458 股股票。股票以平均价格 383.07 美元出售，总交易额为 941,586.06 美元。交易完成后，该董事现在直接拥有 14,895 股公司股票，价值约 5,705,827.65 美元。这代表其持股减少了 14.16%。该销售的披露信息可以在这里找到。5.90% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 Stocks Helping to Bring AI to Healthcare</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只帮助将人工智能引入医疗保健的股票</li>
</ul>
</div><p>A number of brokerages recently issued reports on SYK. JMP Securities reiterated a &#34;market perform&#34; rating on shares of Stryker in a research note on Tuesday, February 18th. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Canaccord Genuity Group increased their price target on Stryker from $420.00 to $435.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, January 29th. Truist Financial raised their target price on Stryker from $409.00 to $413.00 and gave the stock a &#34;hold&#34; rating in a report on Thursday, January 30th. Finally, Wells Fargo &amp; Company raised their price objective on Stryker from $427.00 to $435.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $421.90.</p>
<div class="lb-trans"><p>一些券商最近对 SYK 发布了报告。JMP Securities 在 2 月 18 日的研究报告中重申了对史赛克股票的 “市场表现” 评级。Needham &amp; Company LLC 在 3 月 21 日的研究报告中重新发布了 “买入” 评级，并设定了 442.00 美元的目标价。Canaccord Genuity Group 将史赛克的目标价从 420.00 美元提高到 435.00 美元，并在 1 月 29 日的研究报告中给予该公司 “买入” 评级。Truist Financial 在 1 月 30 日的报告中将史赛克的目标价从 409.00 美元提高到 413.00 美元，并给予该股票 “持有” 评级。最后，Wells Fargo &amp; Company 在 1 月 29 日的报告中将史赛克的目标价从 427.00 美元提高到 435.00 美元，并给予该公司 “增持” 评级。五位分析师对该股票给予了持有评级，十六位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价为 421.90 美元。</p>
</div><p><strong>View Our Latest Stock Report on Stryker</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的史赛克股票报告</strong></p>
</div><h2>Stryker Trading Up 7.7 %</h2>
<div class="lb-trans"><h2>史赛克股票上涨 7.7%</h2>
</div><ul>
<li>Stryker’s Acquisition Spree: Double-Digit Growth on the Horizon</li>
</ul>
<div class="lb-trans"><ul>
<li>史赛克的收购狂潮：双位数增长在望</li>
</ul>
</div><p>SYK opened at $363.44 on Thursday. The stock has a market capitalization of $138.72 billion, a P/E ratio of 46.84, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The firm's fifty day simple moving average is $377.27 and its 200 day simple moving average is $373.71. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.</p>
<div class="lb-trans"><p>周四，SYK 的开盘价为 363.44 美元。该股票的市值为 1387.2 亿美元，市盈率为 46.84，市盈增长比率为 2.93，贝塔系数为 0.93。史赛克的 12 个月低点为 314.93 美元，12 个月高点为 406.19 美元。该公司的 50 日简单移动平均线为 377.27 美元，200 日简单移动平均线为 373.71 美元。该公司的流动比率为 1.95，速动比率为 1.32，债务与股本比率为 0.59。</p>
</div><p>Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 EPS. As a group, research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>史赛克（NYSE:SYK - 获取免费报告）最近在 1 月 28 日星期二宣布了其季度财报。这家医疗技术公司报告第四季度每股收益（EPS）为 4.01 美元，超出分析师共识预期的 3.87 美元，超出幅度为 0.14 美元。史赛克的净利润率为 13.25%，股本回报率为 23.58%。去年同期，该公司每股收益为 3.46 美元。整体来看，研究分析师预计史赛克在当前财年将发布 13.47 美元的每股收益。</p>
</div><h2>Stryker Announces Dividend</h2>
<div class="lb-trans"><h2>史赛克宣布分红</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio is 43.30%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 4 月 30 日星期三支付。3 月 31 日星期一的登记投资者将获得每股 0.84 美元的分红。这相当于年化分红 3.36 美元，收益率为 0.92%。该分红的除息日期为 3 月 31 日星期一。史赛克的分红支付比率为 43.30%。</p>
</div><h2>Stryker Profile</h2>
<div class="lb-trans"><h2>史赛克简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.</p>
<div class="lb-trans"><p>史赛克公司作为一家医疗技术公司运营。该公司通过两个部门运营，分别是医疗外科和神经技术，以及骨科和脊柱。骨科和脊柱部门提供用于全关节置换手术的植入物，如髋关节、膝关节和肩关节，以及创伤和四肢手术。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Stryker</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>First Solar Stock: What's Fueling the Early April Rally?</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>Why Analysts Boosted United Airlines Stock Ahead of Earnings</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Dave &amp; Buster’s Stock: A Short-Squeeze PLAY for Q2</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过史赛克</li>
<li>内部买入解释：投资者需要知道的事项</li>
<li>First Solar 股票：是什么推动了四月初的反弹？</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>为什么分析师在财报前提升了联合航空股票</li>
<li>低市盈率增长股票：解锁投资机会</li>
<li>Dave &amp; Buster’s 股票：第二季度的短期挤压机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=SYK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Stryker Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在史赛克吗？</h2>
</div><p>Before you consider Stryker, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑史赛克之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄向客户推荐在更广泛的市场注意到之前购买……而史赛克并不在名单上。</p>
</div><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管史赛克目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Colonial Trust Advisors 在史赛克公司（NYSE:SYK）持有 1059 万美元的头寸